In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SSI: Revolutionizing Breast Cancer Detection, but Slowly

Executive Summary

Building off conventional ultrasound technology, France's SSI hopes to change the way breast cancer detection is done, reducing the number of unnecessary biopsies by employing elastography to register the stiffness of breast tissue. But as the company seeks to challenge a 3000 year old, low tech approach--manual palpation--company officials are proceeding slowly and are cautious about the claims they make for their technology's innovativeness.

You may also be interested in...



ASBS 2010: Economy, Rise in Mastectomies Temper Minimally Invasive Advancements in Breast Care

Surgeons attending the 11th annual meeting of the American Society of Breast Surgeons were perplexed by the reversal of the trend away from mastectomy and toward breast-conserving therapies. Advanced breast-conserving products were presented at the meeting; but with lowered revenue expectations that can ultimately be attributed to the economic woes of the past couple of years. High unemployment and the lack of health care coverage have prompted many women to delay or forego their yearly mammogram, and as a result, the numbers of biopsies, surgeries, and radiation therapy procedures have declined as well.

Task Force Mammography Guidelines Present Challenges And Opportunities

Mammography coverage policies among public and private payers are not likely to be restricted, at least in the near term, by the U.S. Preventive Services Task Force's new breast cancer screening guidelines, but prospects for longer-term adjustments remain

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel